{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188532","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.658860+00:00","generated_at":"2026-06-13T07:22:42.258165+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novartis discontinues Phase 3 trial of XOMA-licensed NIS793 in pancreatic cancer; continues in colorectal cancer","bullets":["Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.","Trial compared NIS793 plus gem/nab-paclitaxel vs placebo plus gem/nab-paclitaxel; no efficacy or safety established.","Novartis will continue investigating NIS793 in other indications, including a Phase 2 study in colorectal cancer.","XOMA licensed NIS793 to Novartis in September 2015 under a license agreement previously filed with the SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188532","json":"https://secwatch.observer/filing/0001193125-23-188532.json","markdown":"https://secwatch.observer/filing/0001193125-23-188532.md","text":"https://secwatch.observer/filing/0001193125-23-188532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/0001193125-23-188532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/d509906d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:22:42.258165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}